動物実験代替法の国際動向 - nihs.go.jp
動物実験代替法の国際動向 小島 肇 jacvam, nihs 平成25年8月30日、大阪 日本化粧品技術者会 大阪支部勉強会
Download 動物実験代替法の国際動向 - nihs.go.jp
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
NIHS 医薬品安全性情報 Vol.16 No.012018/0111/
www.nihs.go.jpCarafate’]の製品表示が改訂され, 販売名が[‘Carafate suspension’]から [‘Carafate oral suspension’]に変更さ
Guideline for the Development of Liposome Drug …
www.nihs.go.jp4 described in this document are also subject to other relevant notifications and guidelines. The active substances mentioned here include a low-molecular-weight chemical entity, a
Guideline for Bioequivalence Studies of Generic …
www.nihs.go.jp1 Guideline for Bioequivalence Studies of Generic Products for Topical Use July 7, 2003 局所皮膚適用製剤の後発医薬品のための 生物学的同等性試験ガイドライン
Since 1874 遺伝子治療用製品の開発における 国内 …
www.nihs.go.jp遺伝子治療の現状 海外の遺伝子治療の規制と国際調和 日本の遺伝子治療と関連規制 遺伝子治療指針の改正
Guideline for Bioequivalence Studies for Different ...
www.nihs.go.jp2 Section 1: Introduction This guideline describes the principles of procedures of bioequivalence studies for oral solid dosage forms that contains a different quantity of the active ingredient from an
Guidelines, Studies, Solid, Dosage, Guideline for bioequivalence studies for, Bioequivalence, Solid dosage
Clinical Pharmacokinetic Studies of Pharmaceuticals
www.nihs.go.jp- 1 - Clinical Pharmacokinetic Studies of Pharmaceuticals This document is an informal translation of the official text that was promulgated in Japanese on
Pharmaceutical, Clinical, Studies, Clinical pharmacokinetic studies of pharmaceuticals, Pharmacokinetic
平成 25 年度報告 毒物劇物指定の ... - nihs.go.jp
www.nihs.go.jp平成. 25 年度報告 毒物劇物指定のための有害性情報の収集・評価. 物質名: n-(2-
毒物及び劇物取締法Q&A - nihs.go.jp
www.nihs.go.jp1 平成29年3月31日更新 毒物及び劇物取締法Q&A 質問一覧 1.毒物及び劇物取締法について ..... 4
European Medicines Agency - NIHS
www.nihs.go.jpWhat is Quality Risk Management? • Proposed ICH Q9 definition: “Quality risk management is a systematic process for the identification, assessment
Management, European, Quality, Risks, Agency, Quality risk management, Medicine, European medicines agency, Nihs, Ich q9
ICH Q9 ‘Quality Risk Management’ - NIHS
www.nihs.go.jpICH Q9 ‘Quality Risk Management’ - an industry view Peter H. Gough, Eli Lilly and Company
Management, Quality, Risks, Nihs, Ich q9 quality risk management nihs, Ich q9 quality risk management
Related documents
Strategic Plan to Promote the Development and ...
www.epa.govThis Strategic Plan does not constitute rulemaking by the U.S. EPA and cannot be relied on to create a substantive or procedural right enforceable by any party in litigation with the United
MODULO DI SUBENTRO SERVIZI DI TELEFONIA ED ADSL A …
www.infostrada.itmodul isibentdobrvoedolzfafcflplzeboiatlbedlrvoedoiarltdobe poeivoedililbeeeuodrnidaeluolronaissenloauf ziuiloinrsillrorlsiireil:otsoelroesrdlbclpl//(bcl)enr
皮膚感作性試験評価報告書 - JaCVAM
www.jacvam.jp3 . 要旨 皮膚感作性は化学物質の安全性評価において重要な評価項目であり、従来、モルモット やマウスを用いた動物実験によって評価されてきた。
安全データシート - hpc-j.co.jp
www.hpc-j.co.jpジエチレングリコールモノエチルエーテル、林 純薬工業株式会社、a8-19-2、2015/08/10、3/5 保護具 呼吸器の保護具